These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 30594167

  • 1. Association of high body mass index with development of interstitial fibrosis in patients with IgA nephropathy.
    Wu C, Wang AY, Li G, Wang L.
    BMC Nephrol; 2018 Dec 29; 19(1):381. PubMed ID: 30594167
    [Abstract] [Full Text] [Related]

  • 2. Relationship between blood neutrophil-lymphocyte ratio and renal tubular atrophy/interstitial fibrosis in IgA nephropathy patients.
    Chai L, Cai K, Wang K, Luo Q.
    J Clin Lab Anal; 2021 Jun 29; 35(6):e23774. PubMed ID: 33951240
    [Abstract] [Full Text] [Related]

  • 3. Impact of body mass index on progression of primary immunoglobulin a nephropathy.
    Nagaraju SP, Rangaswamy D, Mareddy AS, Prasad S, Kaza S, Shenoy S, Saraf K, Attur RP, Parthasarathy R, Kosuru S, Mateti UV, Guddattu V, Koulmane Laxminarayana SL.
    Saudi J Kidney Dis Transpl; 2018 Jun 29; 29(2):318-325. PubMed ID: 29657199
    [Abstract] [Full Text] [Related]

  • 4. Underweight Is an Independent Risk Factor for Renal Function Deterioration in Patients with IgA Nephropathy.
    Ouyang Y, Xie J, Yang M, Zhang X, Ren H, Wang W, Chen N.
    PLoS One; 2016 Jun 29; 11(9):e0162044. PubMed ID: 27611091
    [Abstract] [Full Text] [Related]

  • 5. Association of obesity with the development of end stage renal disease in IgA nephropathy patients.
    Wang S, Qin A, Dong L, Tan J, Zhou X, Qin W.
    Front Endocrinol (Lausanne); 2023 Jun 29; 14():1094534. PubMed ID: 37020590
    [Abstract] [Full Text] [Related]

  • 6. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
    Zhang X, Shi S, Ouyang Y, Yang M, Shi M, Pan X, Lv J, Wang Z, Ren H, Shen P, Wang W, Zhang H, Xie J, Chen N.
    J Transl Med; 2018 May 03; 16(1):115. PubMed ID: 29724226
    [Abstract] [Full Text] [Related]

  • 7. Cigarette smoking may accelerate the progression of IgA nephropathy.
    Wang S, Qin A, Pei G, Jiang Z, Dong L, Tan J, Tan L, Tang Y, Qin W.
    BMC Nephrol; 2021 Jun 29; 22(1):239. PubMed ID: 34187402
    [Abstract] [Full Text] [Related]

  • 8. Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters.
    Kataoka H, Ohara M, Shibui K, Sato M, Suzuki T, Amemiya N, Watanabe Y, Honda K, Mochizuki T, Nitta K.
    Clin Exp Nephrol; 2012 Oct 29; 16(5):706-12. PubMed ID: 22350469
    [Abstract] [Full Text] [Related]

  • 9. Positive renal familial history in IgA nephropathy is associated with worse renal outcomes: a single-center longitudinal study.
    Sato Y, Tsukaguchi H, Higasa K, Kawata N, Inui K, Linh TNT, Quynh TTH, Yoshihiko I, Koiwa F, Yoshimura A.
    BMC Nephrol; 2021 Jun 19; 22(1):230. PubMed ID: 34147067
    [Abstract] [Full Text] [Related]

  • 10. Association of C4d deposition with clinical outcomes in IgA nephropathy.
    Espinosa M, Ortega R, Sánchez M, Segarra A, Salcedo MT, González F, Camacho R, Valdivia MA, Cabrera R, López K, Pinedo F, Gutierrez E, Valera A, Leon M, Cobo MA, Rodriguez R, Ballarín J, Arce Y, García B, Muñoz MD, Praga M, Spanish Group for Study of Glomerular Diseases (GLOSEN).
    Clin J Am Soc Nephrol; 2014 May 19; 9(5):897-904. PubMed ID: 24578331
    [Abstract] [Full Text] [Related]

  • 11. Uric Acid as a Predictor of Immunoglobulin A Nephropathy Progression: A Cohort Study of 1965 Cases.
    Zhu B, Yu DR, Lv JC, Lin Y, Li Q, Yin JZ, Du YY, Tang XL, Mao LC, Li QF, Sun Y, Liu L, Li XF, Fei D, Wei XY, Zhu CF, Cheng XX, Chen HY, Wang YJ.
    Am J Nephrol; 2018 May 19; 48(2):127-136. PubMed ID: 30110674
    [Abstract] [Full Text] [Related]

  • 12. Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy.
    Zhao YF, Zhu L, Liu LJ, Shi SF, Lv JC, Zhang H.
    Clin J Am Soc Nephrol; 2016 Jun 06; 11(6):947-955. PubMed ID: 27026518
    [Abstract] [Full Text] [Related]

  • 13. Crescentic IgA nephropathy in children.
    Shima Y, Nakanishi K, Hama T, Mukaiyama H, Sato M, Tanaka Y, Tanaka R, Kaito H, Nozu K, Sako M, Iijima K, Yoshikawa N.
    Pediatr Nephrol; 2020 Jun 06; 35(6):1005-1014. PubMed ID: 31993782
    [Abstract] [Full Text] [Related]

  • 14. Clinical and prognostic significance of C1q deposition in IgAN patients-a retrospective study.
    Tian S, Yang X, Luo J, Guo H.
    Int Immunopharmacol; 2020 Nov 06; 88():106896. PubMed ID: 33182045
    [Abstract] [Full Text] [Related]

  • 15. High Neutrophil-To-Lymphocyte Ratio Is an Independent Risk Factor for End Stage Renal Diseases in IgA Nephropathy.
    Wang S, Dong L, Pei G, Jiang Z, Qin A, Tan J, Tang Y, Qin W.
    Front Immunol; 2021 Nov 06; 12():700224. PubMed ID: 34456912
    [Abstract] [Full Text] [Related]

  • 16. Renal Interstitial Inflammation Predicts Nephropathy Progression in IgA Nephropathy: A Two-Center Cohort Study.
    Zhu B, Liu WH, Lin Y, Li Q, Yu DR, Jiang F, Tang XL, Du YY, Yin JZ, Li XF, Zhong YZ, Wang WR, Sun Y, Zhang MJ, Gao YC, Yuan CY, Zhu CF, Cheng XX.
    Am J Nephrol; 2022 Nov 06; 53(6):455-469. PubMed ID: 35576899
    [Abstract] [Full Text] [Related]

  • 17. The MEST score provides earlier risk prediction in lgA nephropathy.
    Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC, Oxford Derivation, North American Validation and VALIGA Consortia, Oxford Derivation North American Validation and VALIGA Consortia.
    Kidney Int; 2016 Jan 06; 89(1):167-75. PubMed ID: 26759049
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes, when matched at presentation, do not vary between adult-onset Henöch-Schönlein purpura nephritis and IgA nephropathy.
    Oh HJ, Ahn SV, Yoo DE, Kim SJ, Shin DH, Lee MJ, Kim HR, Park JT, Yoo TH, Kang SW, Choi KH, Han SH.
    Kidney Int; 2012 Dec 06; 82(12):1304-12. PubMed ID: 22895518
    [Abstract] [Full Text] [Related]

  • 19. Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy.
    Berthoux F, Mariat C, Maillard N.
    Nephrol Dial Transplant; 2013 Nov 06; 28 Suppl 4():iv160-6. PubMed ID: 24026246
    [Abstract] [Full Text] [Related]

  • 20. Histopathologic features aid in predicting risk for progression of IgA nephropathy.
    Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson H, Manns B, Hemmelgarn B.
    Clin J Am Soc Nephrol; 2010 Mar 06; 5(3):425-30. PubMed ID: 20089495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.